Clinical Trial Detail

NCT ID NCT04310397
Title Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

melanoma

Therapies

Dabrafenib + Trametinib

Dabrafenib + Spartalizumab + Trametinib

Age Groups: adult senior

Additional content available in CKB BOOST